Pharmaceutical Preparations
A source-attributed, AI-written analyst report for ATNM.
Every figure is drawn from public filings — the AI writes the analysis, never the numbers.
How the company returns cash to shareholders — from its latest annual SEC filings.
Annual figures from SEC filings · descriptive, not a dividend-safety rating or advice. Delayed data.
Daily OHLC · MA/MACD/RSI computed locally. Not investment advice.
Reference figures from the latest SEC filings.
| Market cap | $26.32M |
|---|---|
| 52-week range | $0.81 – $1.81 |
| Next earnings | Aug 6, 2026 |
Figures from SEC filings · delayed prices · for reference only · not investment advice
Try one backtest free — see how the golden-cross signal performed on this stock.
Sign in to run a free backtestHistorical statistic over past daily data — how this rule behaved before, not a prediction or advice.
Trailing return vs the S&P 500 (SPY) — positive means it outperformed the market.
Trailing price performance vs SPY — a disclosed historical statistic, not a forecast or advice. Delayed data.
How the price has historically moved around past earnings announcements.
A ~2-session move spanning each earnings date — a disclosed historical statistic, not a forecast or advice. Delayed data.
Percentile rank vs Tickwind’s tracked universe — higher = stronger on that factor.
Percentile rank vs Tickwind’s tracked universe. The letter grades are a plain relabeling of these descriptive percentiles; the headline Quant Rating is a disclosed mechanical mapping of the composite percentile — a relative quantitative signal, not personalized investment advice. Delayed data.
Two published academic scores computed from SEC filings — itemized, descriptive, not a rating.
Computed from SEC XBRL filings via published academic formulas (Piotroski 2000; Altman 1968). Zone names are the papers’ published band labels. Descriptive — not a rating, prediction, or investment advice.
Average return by calendar month over the available years.
Historical average monthly returns — a disclosed statistic, not a forecast or advice. Delayed data.
Log in to track ATNM and save links
Keep a watchlist and clip posts from anywhere — free.
Latest SEC filings and headlines for Actinium Pharmaceuticals, Inc. (ATNM).
Actinium Presents New ATNM-400 Data in KRAS and EGFR Mutant Models at SNMMI 2026 Supporting a Mutation-Agnostic Opportunity In Non-Small Cell Lung Cancer
Yahoo · Jun 3, 2026
Actinium Pharmaceuticals Oral Presentation at SNMMI 2026 Highlights ATNM-400 Overcoming Resistance to All Three Approved Androgen Receptor Inhibitors and Offers Flexible, Well-Tolerated Dosing in Prostate Cancer Models
Yahoo · Jun 3, 2026
Actinium's ATNM-400 Reports Preclinical Activity And Combination Synergy Across KRAS- And EGFR-Mutant NSCLC, Supporting Mutation-Agnostic Potential
Benzinga · Jun 3, 2026
Figures from SEC filings · delayed prices · for reference only · not investment advice